Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
Saved in:
| Title: | Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline |
|---|---|
| Authors: | National Comprehensive Cancer Network |
| Source: | Business Wire (English). 09/06/2012. |
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded 11 research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced melanoma and other cancers. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded 11 research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced melanoma and other cancers. [ABSTRACT FROM PUBLISHER] |
|---|
